Literature DB >> 27900390

[Is postoperative radiotherapy necessary in localised standard-risk Ewing sarcoma? : The primary tumor bulk decides upon adjuvant radiotherapy after induction chemotherapy and surgery].

Irenäus A Adamietz1.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 27900390     DOI： 10.1007/s00066-016-1079-4

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN： 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  4 in total

1.  Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial.

Authors:  Marie-Cécile Le Deley; Michael Paulussen; Ian Lewis; Bernadette Brennan; Andreas Ranft; Jeremy Whelan; Gwénaël Le Teuff; Jean Michon; Ruth Ladenstein; Perrine Marec-Bérard; Henk van den Berg; Lars Hjorth; Keith Wheatley; Ian Judson; Heribert Juergens; Alan Craft; Odile Oberlin; Uta Dirksen
Journal:  J Clin Oncol       Date:  2014-06-30       Impact factor: 44.544

2.  Ewing's sarcoma: only patients with 100% of necrosis after chemotherapy should be classified as having a good response.

Authors:  J I Albergo; C L Gaston; M Laitinen; A Darbyshire; L M Jeys; V Sumathi; M Parry; D Peake; S R Carter; R Tillman; A T Abudu; R J Grimer
Journal:  Bone Joint J       Date:  2016-08       Impact factor: 5.082

3.  Can postoperative radiotherapy be omitted in localised standard-risk Ewing sarcoma? An observational study of the Euro-E.W.I.N.G group.

Authors:  Stéphanie Foulon; Bernadette Brennan; Nathalie Gaspar; Uta Dirksen; Lee Jeys; Anna Cassoni; Line Claude; Beatrice Seddon; Perrine Marec-Berard; Jeremy Whelan; Michael Paulussen; Arne Streitbuerger; Odile Oberlin; Heribert Juergens; Robert Grimer; Marie-Cécile Le Deley
Journal:  Eur J Cancer       Date:  2016-05-10       Impact factor: 9.162

Review 4.  A systematic review of optimal treatment strategies for localized Ewing's sarcoma of bone after neo-adjuvant chemotherapy.

Authors:  Joel Werier; Xiaomei Yao; Jean-Michel Caudrelier; Gina Di Primio; Michelle Ghert; Abha A Gupta; Rita Kandel; Shailendra Verma
Journal:  Surg Oncol       Date:  2015-12-11       Impact factor: 3.279
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.